Inspira Technologies Encounters Nasdaq Compliance Issue
Inspira Technologies OXY B.H.N. Ltd., traded on Nasdaq under the symbol IINN, recently announced that it has been notified by the Nasdaq Stock Market about a compliance issue regarding its minimum bid price requirement. On March 10, 2025, the company received a formal notice indicating it has failed to meet the Nasdaq Listing Rule 5550(a)(2), which mandates that companies maintain a minimum closing bid price of $1.00 per share over 30 consecutive business days.
This notification arises from Inspira's Ordinary Shares closing below the required threshold, prompting the company to act swiftly to rectify this situation. According to the Nasdaq guideline, Inspira has been allocated a compliance period of 180 calendar days, ending on September 8, 2025, to regain compliance with the minimum bid price requirement. To do this, Inspira must ensure that its closing bid price meets or exceeds the $1.00 mark for at least 10 consecutive business days within this timeframe.
Should Inspira fail to comply with the minimum bid price by the deadline, it could be granted an additional 180-day compliance period. However, to qualify for this extension, the company would need to adhere to the continued listing requirements, including maintaining the market value of publicly held shares, and must proactively communicate its plans to address this deficiency. This might include measures such as effectuating a reverse stock split if necessary.
The company remains proactive in monitoring its share price and is considering various strategies to meet the Nasdaq requirements within the compliance window. Inspira Technologies assures investors that its Ordinary Shares will continue to be traded on the Nasdaq Capital Market during this period, and the notice received will not immediately affect its trading.
Inspira Technologies is recognized for its innovative contributions to respiratory support and diagnostics. The company’s flagship product, the INSPIRA ART system, is poised to change critical care by allowing patients to receive treatment while awake, thereby stabilizing their oxygen levels without the need for mechanical ventilation. Notably, the INSPIRA ART100 system has received clearance from the FDA for cardiopulmonary bypass procedures in the U.S., alongside additional approvals in Israel for related treatments. Furthermore, its groundbreaking HYLA blood sensor technology is intended to enable real-time blood monitoring without invasive blood draws.
As Inspira Technologies endeavors to navigate this compliance hurdle, it is emphasized that the company is committed to providing innovative medical technologies. The forward-looking statements made by the company regarding its compliance efforts are subject to various factors that may affect outcomes significantly.
In conclusion, while Inspira Technologies faces a challenge concerning its Nasdaq listing, its focus on furthering its innovative medical solutions remains intact. The company plans to utilize the time given by Nasdaq to restore compliance and remain a vital player in the healthcare sector. For further updates or inquiries, stakeholders are encouraged to reach out via the company’s official media relations contact.
For more information about Inspira Technologies and its innovations, please visit
Inspira Technologies' official site.